Retrieve available abstracts of 33 articles: HTML format
Single Articles
September 2025
TAN S, He H, Ni J, Guo Y, et al Meta-analysis evaluating the efficacy and safety of various Bruton tyrosine
kinase (BTK) inhibitors for central nervous system lymphoma: Novel covalent BTK
inhibitors, except for ibrutinib, also demonstrate good efficacy in the treatment
of primary ce
Cancer. 2025;131:e70083. PubMedAbstract available
WITHROW DR, Boyle J, Linet MS, Pittman Ballard CA, et al Determinants of geographic variation in the incidence of adult nonmalignant
meningioma in the United States, 2010-2019.
Cancer. 2025;131:e70042. PubMedAbstract available
August 2025
PERSICO P, Dipasquale A, Losurdo A, Santoro A, et al Primary mismatch repair deficiency and Lynch syndrome in adult diffuse gliomas: A
call to action.
Cancer. 2025;131:e70026. PubMed
RHA SY, Castanon E, Gill S, Senellart H, et al Lenvatinib plus pembrolizumab for patients with previously treated select solid
tumors: Results from the phase 2 LEAP-005 study recurrent glioblastoma cohort.
Cancer. 2025;131:e70015. PubMedAbstract available
TANG LY, Botros D, Kim AA, Khalafallah AM, et al Impact of peri-tumoral resection on survival in primary glioblastoma.
Cancer. 2025;131:e70016. PubMedAbstract available
July 2025
SINGH R, Roubil JG, Bowden G, Mathieu D, et al Clinical outcomes following stereotactic radiosurgery for brain metastases from
sarcoma primaries: An international multicenter analysis.
Cancer. 2025;131:e35931. PubMedAbstract available
June 2025
RETRACTION: Phase 1 Study of Concurrent RMP-7 and Carboplatin with Radiotherapy
for Children with Newly Diagnosed Brainstem Gliomas.
Cancer. 2025;131:e35876. PubMed
NIERENGARTEN MB New standard of care for patients with asymptomatic brain metastases from
melanoma.
Cancer. 2025;131:e35885. PubMed
May 2025
KILICKAP S, Ozguroglu M, Sezer A, Gumus M, et al Cemiplimab monotherapy as first-line treatment of patients with brain metastases
from advanced non-small cell lung cancer with programmed cell death-ligand 1 >/=50.
Cancer. 2025;131:e35864. PubMedAbstract available
April 2025
BERTUCCI A, Dufour O, Appay R, Harlay V, et al Characteristics, outcome, and prognostic factors of young patients with central
nervous system World Health Organization grade 3 oligodendrogliomas IDH-mutant
and 1p/19q codeleted: A French POLA network study.
Cancer. 2025;131:e35814. PubMedAbstract available
March 2025
CANNATARO VL, Bracci PM, Taylor JW, McCoy L, et al Glioma mutational signatures associated with haloalkane exposure are enriched in
firefighters.
Cancer. 2025;131:e35732. PubMedAbstract available
November 2024
SINGER S, Schranz M, Hippler M, Kuchen R, et al Frequency and clinical associations of common mental disorders in adults with
high-grade glioma-A multicenter study.
Cancer. 2024 Nov 17. doi: 10.1002/cncr.35653. PubMedAbstract available
CHAI TS, Rodgers-Fouche LH, Walls JO, Mattia AR, et al Real-world genetic testing outcomes of pan-cancer testing for mismatch repair
deficiency.
Cancer. 2024;130:3888-3893. PubMedAbstract available
October 2024
AHMAD S, Muhlebner A, Snijders TJ, de Leng WW, et al Somatostatin receptor 2A expression in von Hippel-Lindau-related
hemangioblastomas.
Cancer. 2024;130:3473-3479. PubMedAbstract available
July 2024
ASFAW ZK, Hernandez-Marquez GC, Germano IM Patients with glioblastoma: A tale of health care access and genetic ancestry.
Cancer. 2024 Jul 8. doi: 10.1002/cncr.35470. PubMed
May 2024
HSIEH AL, Bi WL, Ramesh V, Brastianos PK, et al Evolving concepts in meningioma management in the era of genomics.
Cancer. 2024 May 16. doi: 10.1002/cncr.35279. PubMedAbstract available
February 2024
ZHOU Y, Guo T, Liang F, Wang Z, et al Cumulative incidence and risk factors of brain metastases in metastatic non-small
cell lung cancer without baseline brain metastasis: Pooled analysis of
individualized patient data from IMpower130, IMpower131, and IMpower150.
Cancer. 2024 Feb 14. doi: 10.1002/cncr.35242. PubMedAbstract available
January 2024
RANJAN S, Leung D, Ghiaseddin AP, Taylor JW, et al Practical guidance for direct oral anticoagulant use in the treatment of venous
thromboembolism in primary and metastatic brain tumor patients.
Cancer. 2024 Jan 30. doi: 10.1002/cncr.35220. PubMedAbstract available
VAN NOT OJ, van den Eertwegh AJM, Haanen JB, van Rijn RS, et al BRAF/MEK inhibitor rechallenge in advanced melanoma patients.
Cancer. 2024 Jan 10. doi: 10.1002/cncr.35178. PubMedAbstract available
October 2023
LI Y, Cao J, Wang J, Wu W, et al Association of the m(6) A reader IGF2BP3 with tumor progression and
brain-specific metastasis in breast cancer.
Cancer. 2023 Oct 20. doi: 10.1002/cncr.35048. PubMedAbstract available
PAPINI C, Willard VW, Gajjar A, Merchant TE, et al Social cognition and adjustment in adult survivors of pediatric central nervous
system tumors.
Cancer. 2023;129:3064-3075. PubMedAbstract available
September 2023
RIEDINGER CJ, Esnakula A, Haight PJ, Suarez AA, et al Characterization of mismatch-repair (MMR)/microsatellite instability
(MSI)-discordant endometrial cancers.
Cancer. 2023 Sep 26. doi: 10.1002/cncr.35030. PubMedAbstract available
LU S, Guo X, Li Y, Liu H, et al Antiprogrammed death ligand 1 therapy failed to reduce the risk of developing
brain metastases in patients with extensive-stage small cell lung cancer: A
retrospective analysis.
Cancer. 2023 Sep 8. doi: 10.1002/cncr.35003. PubMedAbstract available
August 2023
HEFFERNAN AE, Wu Y, Benz LS, Verhaak RGW, et al Quality of life after surgery for lower grade gliomas.
Cancer. 2023 Aug 20. doi: 10.1002/cncr.34980. PubMedAbstract available
MAAS A, Maurice-Stam H, Kremer LCM, van der Aa-van Delden A, et al Psychosocial outcomes in long-term Dutch adult survivors of childhood cancer: The
DCCSS-LATER 2 psycho-oncology study.
Cancer. 2023;129:2553-2567. PubMedAbstract available
BAIREY O, Taliansky A, Glik A, Amiel A, et al A phase 2 study of ibrutinib maintenance following first-line high-dose
methotrexate-based chemotherapy for elderly patients with primary central nervous
system lymphoma.
Cancer. 2023 Aug 12. doi: 10.1002/cncr.34985. PubMedAbstract available
June 2023
BALIGA S, Palmer JD, Yock TI Reply to "Is the hippocampus-sparing attempt really reasonable within the current
technological possibilities?".
Cancer. 2023;129:1779-1780. PubMed
ELMALI A, Mohammadipour S, Yazici G Is the hippocampus-sparing attempt really reasonable within the current
technological possibilities?
Cancer. 2023;129:1777-1778. PubMed
May 2023
MULLER BARK J, Trevisan Franca de Lima L, Zhang X, Broszczak D, et al Proteome profiling of salivary small extracellular vesicles in glioblastoma
patients.
Cancer. 2023 May 31. doi: 10.1002/cncr.34888. PubMedAbstract available
ESTEVEZ-ORDONEZ D, Abdelrashid M, Coffee E, Laskay NMB, et al Racial and socioeconomic disparities in glioblastoma outcomes: A single-center,
retrospective cohort study.
Cancer. 2023 May 28. doi: 10.1002/cncr.34881. PubMedAbstract available
NEFF C, Price M, Cioffi G, Kruchko C, et al Complete prevalence of primary malignant and non-malignant brain tumors in
comparison to other cancers in the United States.
Cancer. 2023 May 18. doi: 10.1002/cncr.34837. PubMedAbstract available
BARDEN MM, Omuro AM Top advances of the year: Neuro-oncology.
Cancer. 2023;129:1467-1472. PubMedAbstract available
April 2023
COLE KA, Ijaz H, Surrey LF, Santi M, et al Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and
irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma.
Cancer. 2023 Apr 20. doi: 10.1002/cncr.34786. PubMedAbstract available